You are here
A Clinical Trial Testing Whether Glucose Metabolism Is an Effective Therapeutic Target in Alzheimer’s Disease
Thiamine (vitamin B1) dependent processes are reduced in Alzheimer’s disease. Thiamine deficiency mimics many aspects of Alzheimer’s disease including the reduced glucose metabolism and exaggeration of the plaque and tangle pathology. Benfotiamine, which is more effective than thiamine at increasing thiamine, diminishes Alzheimer’s disease related pathology. It is also safe. Thus, the therapeutic benefit of benfotiamine is being tested in Alzheimer’s disease patients.